Evidence map›Paper›PMID 40442678›Full record

SynthesisWorld journal of surgical oncology2025

Potential of neoadjuvant hepatic artery perfusion chemotherapy in improving surgical outcomes in hepatocellular carcinoma: a systematic review and meta-analysis.

Zi-Kui Shang, Jian-Hua Zhang, Jia-Hai Zhu, Chuan-Sen Deng, Xi-Yuan Chen, Ran-Xia, Chun-Quan Sun

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zi-Kui Shang *Department of Hepatobiliary Surgery, The Third People's Hospital of Honghe Hani and Yi Autonomous Prefecture, Honghe, 661000, Yunnan Province, China.
Jian-Hua Zhang *Department of Hepatobiliary Surgery, The Third People's Hospital of Honghe Hani and Yi Autonomous Prefecture, Honghe, 661000, Yunnan Province, China.
Jia-Hai ZhuDepartment of Hepatobiliary Surgery, The Third People's Hospital of Honghe Hani and Yi Autonomous Prefecture, Honghe, 661000, Yunnan Province, China.
Chuan-Sen DengDepartment of Hepatobiliary Surgery, The Third People's Hospital of Honghe Hani and Yi Autonomous Prefecture, Honghe, 661000, Yunnan Province, China.
Xi-Yuan ChenDepartment of Hepatobiliary Surgery, The Third People's Hospital of Honghe Hani and Yi Autonomous Prefecture, Honghe, 661000, Yunnan Province, China.
Ran-XiaDepartment of Hepatobiliary Surgery, The Third People's Hospital of Honghe Hani and Yi Autonomous Prefecture, Honghe, 661000, Yunnan Province, China.
Chun-Quan SunDepartment of Hepatobiliary Surgery, The Third People's Hospital of Honghe Hani and Yi Autonomous Prefecture, Honghe, 661000, Yunnan Province, China. 495155735@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe purpose of this study was to assess the effectiveness of adjuvant treatment with new hepatic arterial infusion chemotherapy (HAIC) prior to hepatic resection in patients with resectable hepatocellular carcinoma (HCC).

methodsA systematic review was conducted utilizing established databases and registries as of January 15, 2025, without imposing restrictions based on language, publication date, or status. The inclusion criteria were met by studies that examined the effects of HAlC, with or without surgical intervention, in comparison to surgical treatment alone. The primary outcomes encompassed overall survival (OS) and disease-free survival (DFS), while secondary outcomes included recurrence rate and adverse events. A random effects model was employed to analyze the data.

resultsA total of 10 studies involving 1,014 patients were included. The results showed that preoperative HAlC improved patient survival (OS), disease-free survival (DFS), and recurrence rates compared with surgical treatment alone. The most common grade 3 and higher adverse reactions in patients treated with preoperative HAIC included vomiting, leukopenia, neutropenia, hypothyroidism, and diarrhea.

conclusionPreoperative HAIC has been demonstrated to enhance survival outcomes in patients with resectable HCC; however, the clinical efficacy of this approach requires further validation through large-scale design studies.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularHepatectomyLiver NeoplasmsNeoadjuvant TherapyNeoplasm Recurrence, LocalChemotherapy, AdjuvantDisease-Free SurvivalHepatic ArteryHumansInfusions, Intra-ArterialPrognosisSurvival RateHepatectomyHepatic artery infusion chemotherapyNeoadjuvant therapyPrimary liver cancer

Identifiers

PMID40442678
PMCPMC12123804

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.